RxDoctor Payments Data

Sanjiv Dalvi, MD

Internal Medicine · Fayetteville, NCNPI 1881763944

Payments from drug & device makers

$23,728in general payments, 2019–2025

Across 762 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$23,702100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca65$3,055
Amgen(2 entities)74$2,165
Novo Nordisk73$2,047
Lilly USA, LLC66$1,639
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)47$1,566
AbbVie(2 entities)35$1,245
Sanofi-aventis U.S. LLC27$833
GSK38$831
Abbott19$709
Novartis40$708
Eisai Inc.20$704
Boehringer Ingelheim26$656
Johnson & Johnson8$519
Medtronic6$491
Bayer18$480
Pfizer15$476
Esperion Therapeutics, Inc.18$451
Otsuka America Pharmaceutical, Inc.6$432
Radius Health, Inc.13$429
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$374
Amarin Pharma, Inc.19$371
Ironwood Pharmaceuticals, Inc9$310
Phathom Pharmaceuticals, Inc.5$276
Exact Sciences6$236
Mylan Specialty L.p.4$177
Merck6$174
Takeda Pharmaceuticals U.S.A., Inc.9$170
Organogenesis Inc.2$160
Lexicon Pharmaceuticals, Inc.3$160
Teva Pharmaceuticals USA, Inc.4$158
Biohaven Pharmaceuticals, Inc.3$145
Corcept Therapeutics2$132
Galderma Laboratories, L.p.1$125
Biohaven Pharmaceutical Holding Company Ltd.1$124
UCB, Inc.5$121
Nevro Corp.1$104
Axsome Therapeutics, Inc.2$103
Idorsia Pharmaceuticals US Inc1$100
Biogen4$93
Kowa Pharmaceuticals America, Inc.7$84
Sunovion Pharmaceuticals Inc.4$66
Quidel Corporation2$57
Viatris Specialty LLC2$53
TMS Neurohealth Centers Inc.2$50
ARS Pharmaceuticals Operations, Inc.2$45
Supernus Pharmaceuticals, Inc.3$41
Astellas Pharma US Inc2$33
Azurity Pharmaceuticals, Inc.2$30
IBSA Pharma Inc.1$24
Fidia Pharma USA Inc.1$24
Aytu Biopharma, Inc.1$22
CMP Pharma, Inc.1$19
Lundbeck LLC1$17
Daiichi Sankyo Inc.1$17
Hikma Pharmaceuticals USA1$16
Scilex Pharmaceuticals Inc.1$15
Gilead1$14
Boston Scientific1$13
Assertio Therapeutics, Inc.1$13
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,728 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$315,594
Medicare patients
373
Services billed
24,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$72,077
OzempicSemaglutide45$54,640
JardianceEmpagliflozin46$52,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$45,414
TrulicityDulaglutide34$43,970
FarxigaDapagliflozin Propanediol40$43,561
EliquisApixaban33$39,295
RybelsusSemaglutide28$37,425
LinzessLinaclotide25$33,972
KerendiaFinerenone15$17,681
EntrestoSacubitril/Valsartan11$14,468
MyrbetriqMirabegron12$13,865
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,192
BrilintaTicagrelor12$10,161
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$7,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,639$116,04780 claims
Novo NordiskOzempic, Rybelsus$2,047$92,06673 claims
AstraZenecaFarxiga, Brilinta$3,055$53,72252 claims
Boehringer IngelheimJardiance$656$52,93946 claims
GSKTrelegy Ellipta$831$45,41453 claims
PfizerEliquis$476$39,29533 claims
AbbVieLinzess$1,245$33,97225 claims
BayerKerendia$480$17,68115 claims
NovartisEntresto$708$14,46811 claims
Astellas Pharma US IncMyrbetriq$33$13,86512 claims
Scilex Pharmaceuticals Inc.Colchicine$15$2,00718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →